FDA Class I Recall: Abbott FreeStyle Libre 3 Continuous Glucose Monitoring System

Friday, 6 September 2024, 10:05

FDA has issued a Class I recall for Abbott's FreeStyle Libre 3 continuous glucose monitoring system. This recall affects the FreeStyle Libre 3 sensor, which is critical for diabetes management. Understanding the implications of this recall is essential for patients and healthcare providers alike.
LivaRava_Medicine_Default.png
FDA Class I Recall: Abbott FreeStyle Libre 3 Continuous Glucose Monitoring System

Overview of FDA's Class I Recall

The FDA has announced a Class I recall affecting the Abbott FreeStyle Libre 3 continuous glucose monitoring (CGM) system. This decision comes after concerns regarding the functionality of the FreeStyle Libre 3 sensor, pivotal for many individuals managing diabetes.

Details on the FreeStyle Libre 3 System

  • The FreeStyle Libre 3 is a continuous glucose monitor designed to give real-time glucose readings.
  • Abbott’s FreeStyle Libre series generated impressive revenue, approximately $1.4 billion last year.
  • Patients depend on the reliability of these systems for effective diabetes management.

What Patients Should Do

  1. Consult healthcare providers regarding this recall and its impact on glucose monitoring.
  2. Consider alternative glucose monitoring options if recommended.
  3. Stay informed about updates from Abbott and the FDA.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe